490 related articles for article (PubMed ID: 19465589)
1. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Suzuki K; Tanaka Y
Rheumatology (Oxford); 2009 Aug; 48(8):1012-3. PubMed ID: 19465589
[No Abstract] [Full Text] [Related]
2. Efficacy of combination therapy of anti-TNF-α antibody infliximab and methotrexate in refractory entero-Behçet's disease.
Iwata S; Saito K; Yamaoka K; Tsujimura S; Nawata M; Hanami K; Tanaka Y
Mod Rheumatol; 2011 Apr; 21(2):184-91. PubMed ID: 21052764
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of refractory Behçet's disease with the TNF-alpha blocker infliximab.
Jalili A; Kinaciyan T; Barisani T; Peck-Radosavljevic M; Stingl G; Geusau A; Wöhrl S
Iran J Immunol; 2009 Mar; 6(1):55-8. PubMed ID: 19293479
[No Abstract] [Full Text] [Related]
4. [Behçet's disease and the possibilities of modern tumour necrosis factor inhibiting medication].
van Laar JA; Jamnitski A; Baarsma GS; van Daele PL; van Hagen PM
Ned Tijdschr Geneeskd; 2006 Apr; 150(13):705-9. PubMed ID: 16623340
[TBL] [Abstract][Full Text] [Related]
5. Treat early and embrace the evidence in favour of anti-TNF-alpha therapy for Behçet's uveitis.
Lee RW; Dick AD
Br J Ophthalmol; 2010 Mar; 94(3):269-70. PubMed ID: 20215370
[No Abstract] [Full Text] [Related]
6. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
Sarwar H; McGrath H; Espinoza LR
J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
[TBL] [Abstract][Full Text] [Related]
7. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of genital ulcers with infliximab in Behcet's disease.
Haugeberg G; Velken M; Johnsen V
Ann Rheum Dis; 2004 Jun; 63(6):744-5. PubMed ID: 15140785
[No Abstract] [Full Text] [Related]
10. Effect of infliximab on refractory uveitis in Behcet's disease.
Sayarlioglu M; Cinal A; Topcu N; Demirok A
Ann Pharmacother; 2004 May; 38(5):901-2. PubMed ID: 15010522
[No Abstract] [Full Text] [Related]
11. Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease.
Park J; Cheon JH
Gut Liver; 2018 Nov; 12(6):623-632. PubMed ID: 29788675
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-alpha therapy for uveitis: Behçet and beyond.
Murray PI; Sivaraj RR
Eye (Lond); 2005 Aug; 19(8):831-3. PubMed ID: 16086039
[No Abstract] [Full Text] [Related]
13. Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
Benitez-del-Castillo JM; Martinez-de-la-Casa JM; Pato-Cour E; Méndez-Fernández R; López-Abad C; Matilla M; Garcia-Sanchez J
Eye (Lond); 2005 Aug; 19(8):841-5. PubMed ID: 15389273
[TBL] [Abstract][Full Text] [Related]
14. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
[TBL] [Abstract][Full Text] [Related]
15. A case of severe MAGIC syndrome treated successfully with the tumor necrosis factor-alpha inhibitor infliximab.
Geissal ED; Wernick R
J Clin Rheumatol; 2010 Jun; 16(4):185-7. PubMed ID: 20414125
[TBL] [Abstract][Full Text] [Related]
16. Sustained remission after infliximab in a child with vasculitis refractory to conventional immunosuppressives including interferon-alpha.
Evereklioglu C; Borlu M
Br J Ophthalmol; 2008 Aug; 92(8):1034, 1148-9. PubMed ID: 18653594
[No Abstract] [Full Text] [Related]
17. [Efficacy of TNF-alpha antagonist and other immunomodulators in the treatment of patients with ophthalmologic manifestations of Behcet's disease and HLA B51 positive vasculitis].
Zlatanović G; Jovanović S; Veselinović D; Zivković M
Vojnosanit Pregl; 2012 Feb; 69(2):168-74. PubMed ID: 22500372
[TBL] [Abstract][Full Text] [Related]
18. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
19. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
20. A patient with neuro-Behçet's disease is successfully treated with etanercept: further evidence for the value of TNFalpha blockade.
Alty JE; Monaghan TM; Bamford JM
Clin Neurol Neurosurg; 2007 Apr; 109(3):279-81. PubMed ID: 17174468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
